Academician Yu Hu: World Pioneer in Dual-Target CAR-T Therapy for Multiple Myeloma & Thrombosis at Wuhan Union Hospital

1. Academic & Clinical Leadership: China's Vanguard in Hematology

Academician Yu Hu is an internationally celebrated hematologist and clinician-scientist serving at Wuhan Union Hospital, affiliated with Tongji Medical College of Huazhong University of Science and Technology (HUST). As an Academician of the Chinese Academy of Engineering (CAE) and Director of the Institute of Hematology, Academician Hu stands at the apex of hematological malignancy care and cellular immunotherapy globally.

Wuhan Union Hospital’s hematology center is designated as a National Key Clinical Specialty and one of the largest comprehensive hematology diagnosis and treatment hubs in Asia. Under Academician Hu’s stewardship, the center has become a premier global destination for innovative cellular therapies, resolving end-stage hematological cases previously deemed untreatable.

2. Primary Clinical Focus & Hematological Conditions Managed

Academician Yu Hu and his multidisciplinary team specialize in tertiary consultations and frontier cellular immunotherapies for complex blood disorders:

• Relapsed & Refractory Multiple Myeloma (RRMM): Pioneer in dual-target and novel engineered CAR-T cell infusions for myeloma patients who have progressed through proteasome inhibitors, immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies.
• Venous Thromboembolism (VTE) & Hereditary Thrombophilia: Leading Asia's most comprehensive program in complex deep vein thrombosis (DVT), pulmonary embolism (PE), and recurrent atypical thrombosis management.
• Immune Thrombocytopenia (ITP) & Platelet Disorders: Precision phenotyping and refractory management for corticosteroid-resistant and splenectomy-refractory ITP using targeted thrombopoietin receptor agonists (TPO-RAs) and immune-resetting regimens.
• Leukemia & Lymphoma Cellular Protocols: Tailored bridging strategies, targeted bispecific antibodies, and autologous/allogeneic stem cell transplantation.

3. Landmark Scientific Research: From The Lancet to Blood

Academician Hu's laboratory and clinical trial groups consistently produce paradigm-shifting discoveries featured in top-tier medical journals:

• The Lancet: World's First In Situ CAR-T Therapy for Multiple Myeloma: Published landmark clinical data validating the safety and dramatic tumor-clearing efficacy of engineered in situ CAR-T cells, offering unprecedented remission rates for heavily pretreated, multi-refractory myeloma patients worldwide.
• 2025 Blood: Immune Resetting & TPO-RA Discontinuation in ITP: Decoded the immunological mechanisms governing why certain ITP patients relapse after stopping thrombopoietin receptor agonists, creating a predictive biomarker framework that guides successful long-term medication withdrawal without disease recurrence.
• Asia’s Largest Venous Thrombosis Biobank & Gene Chips: Established an extensive clinical and genetic specimen library comprising tens of thousands of thromboembolism profiles. Academician Hu translated these findings into commercialized molecular diagnostic chips that identify patient-specific thrombophilia risk profiles.

4. Transformative Clinical Innovations

Academician Hu's contributions have directly rewritten standard clinical algorithms:

• Dual-Target CAR-T Protocols: Pioneered dual-targeted chimeric receptor strategies (such as BCMA/CD19 and BCMA/GPRC5D) that target distinct plasma cell antigens simultaneously, drastically preventing antigen escape and significantly prolonging progression-free survival (PFS).
• Revolutionizing Thrombosis Recurrence Prevention: By applying his precision molecular diagnostic scoring system to guide the duration and intensity of anticoagulation, Academician Hu's team successfully slashed 5-year thrombosis recurrence rates from 26.6% down to 5.6%.
• Minimizing Cytokine Release Syndrome (CRS): Engineered stepped pre-infusion cytoreduction and precise anti-IL-6/corticosteroid intervention protocols, making high-potency CAR-T therapy significantly safer for elderly and frail myeloma patients.

5. Benchmark Clinical Case Scenarios

Academician Hu’s unit routinely provides life-saving interventions for patients who have exhausted standard clinical options globally:

• Case Scenario 1 (Multi-Refractory Multiple Myeloma Salvage): A patient with penta-refractory multiple myeloma and extensive osteolytic bone lesions refractory to chemotherapy, daratumumab, and standard maintenance therapy received Academician Hu's proprietary dual-target CAR-T regimen. Within 28 days post-infusion, bone marrow minimal residual disease (MRD) achieved 10^-6 negativity, with sustained complete response and robust bone remineralization.
• Case Scenario 2 (Severe Recurrent Thrombophilia Management): A patient who suffered recurrent unprovoked pulmonary embolisms despite standard therapeutic anticoagulation underwent genetic profiling via Academician Hu’s diagnostic chip. A novel compound heterozygous thrombophilic mutation was identified, allowing a customized non-vitamin K anticoagulant and anti-platelet strategy that achieved 4-year recurrence-free stability.

6. Accessing Academician Yu Hu for International Patients

International patients seeking expert hematological evaluation, CAR-T clinical assessment, or thrombophilia risk management can access Academician Yu Hu through organized medical coordination:

1. Hematology Dossier Assembly: Serial bone marrow aspirate and biopsy reports (with immunohistochemistry), flow cytometry MRD analyses, serum/urine protein electrophoresis (SPEP/UPEP), serum free light chain (sFLC) ratios, cytogenetic FISH panels, and digital PET/CT or whole-body low-dose CT scans.
2. Pre-Screening & CAR-T Eligibility Triage: Comprehensive evaluation of organ function, cardiac reserves, and immune status to assess eligibility for cell collection and therapeutic infusion protocols.
3. Physician Review & Personalized Strategy: Authorized review of patient records by Academician Hu’s specialist panel for definitive staging, prognostic stratification, and individualized therapeutic scheduling.
4. Comprehensive Concierge Support: For admitted patients, dedicated coordination including medical visa documentation, cellular therapy scheduling, specialized HEPA laminar flow inpatient suite reservations, bilingual bedside support, and long-term remote monitoring.

7. Inquire & Request a Clinical Assessment

China Medical Concierge - Shanghai (CMCS) is an independent health management and medical concierge service. We connect international patients and expatriates with leading specialists and premier national academic medical centers across China.

To inquire about case reviews, CAR-T eligibility assessments, or coordination with Academician Yu Hu’s hematology team, please reach out directly through our official channels: